Cargando…
Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer
Immune checkpoint inhibitors (ICIs), a type of immunotherapy, have become one of the most important therapeutic options for first- and second-line treatment of advanced non-small cell lung cancer (NSCLC). Recent clinical studies have shown that immunotherapy can offer substantial survival benefits t...
Autores principales: | Guo, Hanfei, Li, Wenqian, Qian, Lei, Cui, Jiuwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8181868/ https://www.ncbi.nlm.nih.gov/pubmed/34158740 http://dx.doi.org/10.21147/j.issn.1000-9604.2021.02.08 |
Ejemplares similares
-
Advances and challenges in immunotherapy of small cell lung cancer
por: Guo, Hanfei, et al.
Publicado: (2020) -
Coexisting opportunities and challenges: In which scenarios can minimal/measurable residual disease play a role in advanced non-small cell lung cancer?
por: Guo, Hanfei, et al.
Publicado: (2021) -
Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer
por: Bai, Rilan, et al.
Publicado: (2020) -
Neoadjuvant immunotherapy in resectable non-small-cell lung cancer
por: Chen, Lanyi Nora, et al.
Publicado: (2023) -
Challenges of evaluating immunotherapy efficacy in solid tumors
por: Bai, Rilan, et al.
Publicado: (2019)